Compare Boeing Co (BA) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boeing Co vs BioNano Genomics Inc — how do they compare? Boeing Co trades at $234 (market cap $184.35B), while BioNano Genomics Inc trades at $1.19 (market cap $13.66M). The key difference: Boeing Co is far larger — about 13495.6× BioNano Genomics Inc's market cap, and Boeing Co pays a 0.03% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BA | BNGO | |
|---|---|---|
Market Cap | $184.35B | $13.66M |
Volume | 7,591,579 | — |
Sector | Industrials | Health |
52-Week High | $252.15 | $4.92 |
52-Week Low | $179.12 | $1.06 |
Enterprise Value | $210.23B | $16.26M |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $232.79, down 0.7% on the day, with a bullish technical signal supported by moving averages. The company reported revenue of $89.46B in 2025, swinging to a net income of $2.24B, and recent news highlights its strategic sale of non-core aviation technology units to Archer Aviation to sharpen focus on core aerospace and defense operations.
The outlook is positive with a consensus price target of $280.83, though high valuation ratios and volatile cash flows pose risks. Earnings momentum is mixed, with a recent Q2 2026 EPS miss, but analyst sentiment remains strongly bullish with 67% buy ratings.
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
